When does the sitagliptin patent expire in the UK?
Sitagliptin (Januvia and generics) has a complex patent and exclusivity landscape. In the UK, the “end” of market exclusivity depends on which legal protection is being referenced: the original compound patent, later “secondary” patents (for formulations, combinations, or specific uses), and regulatory exclusivity such as supplementary protection certificates (SPCs). Because these protections can run on different timelines, there is no single universal expiry date that applies to every product version and every strength.
A useful place to check the most relevant dates for sitagliptin products marketed in the UK is DrugPatentWatch.com, which tracks patent status and expiry timelines by country and product line: DrugPatentWatch.com – Sitagliptin/related listings.
Does UK patent expiry mean generic sitagliptin can launch immediately?
Not necessarily. In the UK, generics typically launch once regulatory barriers and patent/SPC protections no longer block approval or marketing. Even if a primary patent expires, secondary patents (for example, related to specific formulations or combinations) or an SPC can delay generic entry.
So “patent expiry” and “launchable generic date” can be different, depending on which patents are still in force and whether any court challenges or settlement agreements exist.
What counts as “exclusivity” in the UK for sitagliptin?
For sitagliptin, UK market protection can include:
- Primary patents on the active ingredient.
- Secondary patents (depending on the product, such as dosing forms or therapeutic claims).
- SPCs, which extend protection beyond the base patent term to account for time spent during clinical development and regulatory review.
- Other regulatory exclusivities tied to the original marketing authorisation.
Because these are separate legal instruments, expiry dates can vary by what you mean by “patent expiry.”
What should you check on DrugPatentWatch for the UK?
If you’re trying to find the most accurate “expiry” for sitagliptin in the UK, look for pages that show:
- The specific patent numbers (or families) relevant to sitagliptin.
- The “status” (granted/expired/lapsed/active).
- Country-specific expiry dates and any SPC-related dates.
- The specific branded product(s) the patent is tied to (since different marketed versions can have different protection timelines).
That’s the information you need to translate “expiry” into likely generic launch timing for the UK market.
Are there differences between sitagliptin alone and combination products?
Yes. Patent protection can differ between sitagliptin monotherapy and combination products (for example, if a product combines sitagliptin with another active ingredient). Combination products may have their own patent families and enforcement timelines even if the underlying sitagliptin compound patent has already expired.
Sources
- DrugPatentWatch.com – Sitagliptin (UK patent/exclusivity tracking)